Syndax Pharmaceuticals
SNDX
175 hedge funds and large institutions have $1.03B invested in Syndax Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 76 increasing their positions, 59 reducing their positions, and 11 closing their positions.
82% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 11
29% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 59
5% more funds holding
Funds holding: 166 → 175 (+9)
0.46% less ownership
Funds ownership: 102.67% → 102.21% (-0.46%)
2% less call options, than puts
Call options by funds: $66.1M | Put options by funds: $67.5M
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
30% less capital invested
Capital invested by funds: $1.48B → $1.03B (-$447M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$16.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.3M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$14.4M |
| 4 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
+$12M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$58.8M |
| 2 |
O
OrbiMed
New York
|
-$23.6M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$12.1M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$10.9M |
| 5 |
State Street
Boston,
Massachusetts
|
-$10.5M |
SNDX Hedge Fund Activity: Q3 2023 in Review
175 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2023, worth a combined $1.03B — down 30% from $1.48B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new SNDX positions and 11 closed out — a net gain of 9 holders — while 76 added to existing stakes and 59 trimmed.
The largest buyer was BlackRock, adding an estimated $16.9M. The largest seller was Frazier Life Sciences Management, cutting an estimated $58.8M.
- 175 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2023, up from 166 in Q2 2023.
- Funds reported $1.03B of Syndax Pharmaceuticals stock for Q3 2023, down 30% quarter-over-quarter.
- 20 funds opened new Syndax Pharmaceuticals positions in Q3 2023 and 11 closed out, a net change of +9 holders.
- The largest Syndax Pharmaceuticals buyer in Q3 2023 was BlackRock, an estimated $16.9M added.
- The largest Syndax Pharmaceuticals seller in Q3 2023 was Frazier Life Sciences Management, an estimated $58.8M sold.
Based on aggregated 13F filings for Q3 2023.